Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 1, 2017, Pages 50-62

  Colombel, J F ^a   Jharap, B ^b   Sandborn, W J ^c   Feagan, B ^d   Peyrin Biroulet, L ^e   Eichner, S F ^f   Robinson, A M ^f   Mostafa, N M ^f   Zhou, Q ^f   Thakkar, R B ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; PLACEBO; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOGENICITY; INFECTION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; STOMACH CANCER; ULCERATIVE COLITIS; ADULT; BLOOD; CLINICAL TRIAL; COLITIS, ULCERATIVE; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; MALE; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84997712942     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13838     Document Type: Article

References (33)

1. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–33.
2. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829–38.
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52–65.
4. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102–11.
5. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780–7.
6. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257–65; e1–3.
7. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383–95.
8. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392–400 e3.
9. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268–74.
10. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141: 1612–20.
11. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621–8.
12. Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis 2011; 17: 1423–7.
13. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121–5.
14. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617–25.
15. Beigel F, Steinborn A, Schnitzler F, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014; 23: 735–44.
16. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014; 146: 941–9.
17. Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 2015; 13: 1293–301 e5.
18. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36–41 e1.
19. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013; 19: 1112–22.
20. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700–21.
21. Humira (adalimumab). Full Prescribing Information, AbbVie Inc., North Chicago, IL, 2015.
22. Noertersheuser PA, Eckert D, Sharma S, et al. Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD. Gastroenterology 2013; 144(5 (Suppl. 1)): S–230.
23. Awni WM, Eckert D, Sharma S, et al. Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis. Gastroenterology 2013; 144(5 (Suppl. 1)): S–229.
24. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210–26.
25. Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-TNF therapy for Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2015; 13: 2233–40.
26. Kopylov U, Al-Taweel T, Yaghoobi M, et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8: 1632–41.
27. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNFα therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2015; 14: 550–7.
28. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861–8.
29. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226–31.
30. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444–7.
31. Velagapudi R, Noertersheuser P, Awni W, et al. Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA, Abbott), following a single intravenous (iv) injection. Arthritis Rheum 2003; 48: S141.
32. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015; 74: 1037–44.
33. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut 2014; 63: 1843–53.